8-K: Haemonetics Reports Solid Fiscal 2025 Results and Issues Fiscal 2026 Guidance

Haemonetics Corporation reports fourth quarter and fiscal year 2025 results, showing revenue growth and margin expansion, and provides fiscal 2026 guidance.

Summary

• Haemonetics Corporation reported a (4)% decrease in revenue for the fourth quarter of fiscal 2025, totaling $331 million.
• However, fiscal year 2025 revenue increased by 4% to $1.361 billion.
• Earnings per diluted share for the fourth quarter were $1.17, and adjusted earnings per diluted share were $1.24.
• For the full fiscal year, earnings per diluted share were $3.31, and adjusted earnings per diluted share were $4.57.
• Cash flow from operating activities for fiscal 2025 was $182 million, and free cash flow was $145 million.
• The company's gross margin increased to 58.4% in the fourth quarter, driven by volume growth in the Hospital segment and pricing benefits.
• Operating expenses decreased by 16.6% in the fourth quarter due to the remeasurement of contingent consideration and lower performance-based compensation.
• Haemonetics' CEO, Chris Simon, stated that the company is on track to deliver all the goals of its four-year long-range plan in fiscal 2026.
• The company has issued fiscal 2026 guidance, projecting total revenue growth between (3)% and 6% and organic revenue growth between (2)% and 1%.
• Adjusted operating margin is expected to be between 26% and 27%, with adjusted earnings per diluted share between $4.70 and $5.00.
• Free cash flow is projected to be between $160 million and $200 million.
• The Board of Directors approved a new share repurchase authorization of up to $500 million over the next three years.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company reported solid earnings growth and margin expansion for the full fiscal year, the fourth quarter revenue decline and relatively low fiscal 2026 growth guidance temper the overall outlook. The share repurchase program and cost-saving initiatives are positive signals.

Positives

• Fiscal year 2025 saw solid earnings growth, record margin expansion, and strong cash flow.
• The Hospital segment experienced significant revenue growth.
• The company has a strong cash position, with $306.8 million on hand as of March 29, 2025.
• The new share repurchase program indicates confidence in the company's financial position and future prospects.
• The company is implementing a new market and regional alignment initiative expected to yield $30 million in annualized savings.

Negatives

• Fourth quarter fiscal 2025 revenue decreased by (3.7)% compared to the same period last year.
• Plasma revenue decreased by (9.1)% in the fourth quarter of fiscal 2025.
• Blood Center revenue decreased by (22.2)% in the fourth quarter of fiscal 2025.
• Fiscal 2026 revenue growth guidance is relatively low, with organic growth projected between (2)% and 1%.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including market conditions, competitive products, and regulatory uncertainties.
• The company's ability to realize the anticipated strategic benefits and opportunities from acquisitions and divestitures is not guaranteed.
• The company faces risks related to manufacturing, distribution, and supply chain disruptions.
• The company's indebtedness could impact its financial flexibility.
• The company's new market and regional alignment initiative may not be implemented as planned, and the expected cost savings may not be fully realized.

Future Outlook

Haemonetics projects fiscal 2026 total revenue growth between (3)% and 6%, organic revenue growth between (2)% and 1%, adjusted operating margin between 26% and 27%, adjusted earnings per diluted share between $4.70 and $5.00, and free cash flow between $160 million and $200 million.

Management Comments

• Chris Simon, Haemonetics CEO, stated: 'We delivered solid earnings growth in our fiscal 2025, with record margin expansion and strong cash flow as evidence of the health and vitality of our businesses.'
• Chris Simon, Haemonetics CEO, stated: 'Our industry-leading NexSys, TEG and VASCADE technologies continue to propel our growth in attractive markets, and we are on track to deliver all of the goals of our four-year long-range plan in fiscal 2026.'

Industry Context

Haemonetics operates in the medical technology industry, providing solutions for hospitals, plasma centers, and blood centers. The company's performance is influenced by factors such as healthcare cost containment trends, industry consolidation, and regulatory changes. The company competes with other medical technology companies in these markets.

Comparison to Industry Standards

• It is difficult to provide a direct comparison to industry standards without more specific information on Haemonetics' competitors and their recent performance.
• However, the company's focus on margin expansion and cash flow generation aligns with industry trends.
• Companies like Medtronic, Baxter, and Abbott are major players in the broader medical technology space, and their financial performance can serve as a general benchmark.
• Haemonetics' growth rates in specific segments like Hospital can be compared to the growth rates of these larger companies in similar product categories.

Stakeholder Impact

• Shareholders may benefit from the share repurchase program and potential for increased earnings.
• Employees may be affected by the market and regional alignment initiative, which includes potential severance and other employee costs.
• Customers may benefit from the company's focus on improving the quality, effectiveness, and efficiency of healthcare.
• Suppliers may be impacted by the company's cost-saving initiatives and portfolio rationalization.

Next Steps

• The company will continue to execute its four-year long-range plan.
• The company will implement its new market and regional alignment initiative.
• The company will repurchase shares under its new $500 million authorization.
• The company will focus on internal investments and inorganic opportunities to accelerate long-term growth.

Key Dates

Keywords

Haemonetics, financial results, fiscal 2025, fiscal 2026 guidance, revenue, earnings, share repurchase, plasma, blood center, hospital, operating margin, free cash flow